Pfizer reports promising results in first phase of vaccine trial

The trial gave 24 of its 45 participants two doses of the coronavirus vaccine, and all 24 produced antibodies. The vaccine will undergo two more trials before possible approval, which Pfizer hopes to get by the end of the year.